Sees FY26 Revenue at $6.4B-$6.7B, Consensus $6.64B
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Mar 04 2026
0mins
Should l Buy ARDT?
Sees FY26 revenue $6.4B-$6.7B, consensus $6.64B
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy ARDT?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on ARDT
Wall Street analysts forecast ARDT stock price to rise
13 Analyst Rating
8 Buy
4 Hold
1 Sell
Moderate Buy
Current: 9.240
Low
10.00
Averages
13.73
High
17.00
Current: 9.240
Low
10.00
Averages
13.73
High
17.00
About ARDT
Ardent Health, Inc., formerly Ardent Health Partners, Inc., is a provider of healthcare in mid-sized urban communities across the United States. Through its subsidiaries, the Company delivers care through a system of 30 acute care hospitals and approximately 280 sites of care with over 1,800 affiliated providers across six states. It provides both general and specialty services, including internal medicine, general surgery, cardiology, oncology, orthopedics, women’s services, neurology, urology, and emergency services, within inpatient and ambulatory care settings. In addition to its 30 acute care hospitals, it operates a network of ambulatory facilities and telehealth services, including primary care and specialty care clinics, ambulatory surgery centers (ASCs), urgent care centers, free-standing emergency departments, and diagnostic imaging centers. It operates a consumer-centric healthcare platform focused on creating relationships with its patients across multiple care settings.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Class Action Lawsuits Filed Against Varonis and Ardent Health
- Varonis Lawsuit Overview: Shareholders of Varonis Systems, Inc. are facing losses from February 4 to October 28, 2025, due to the company's failure to disclose its ability to sustain growth, leading to a misunderstanding of its prospects, with a class action deadline of March 9, 2026.
- Ardent Lawsuit Details: Similarly, shareholders of Ardent Health, Inc. from July 18, 2024, to November 12, 2025, encountered issues as the company misrepresented the collectability of accounts receivable, resulting in a misjudgment of its financial health, with the same class action deadline of March 9, 2026.
- Legal Consultation Advice: The Law Offices of Frank R. Cruz remind investors who suffered losses during the specified periods to contact the firm to understand their legal rights, providing contact details including phone and email.
- Class Action Participation Note: Investors need not take immediate action to be part of the class action, and the law firm offers various contact methods for shareholders to obtain more information and consultation.
See More
Class Action Lawsuit Reminder Against Ardent Health, Inc.
- Class Action Notification: The Schall Law Firm reminds investors of a class action lawsuit against Ardent Health, Inc. (NYSE: ARDT) for securities purchased between July 18, 2024, and November 12, 2025, urging affected investors to contact the firm by March 9, 2026, to participate.
- False Statement Allegations: The complaint alleges that Ardent made false and misleading statements, claiming reliance on 'detailed reviews of historical collections' to assess collectible accounts receivable, which was not the case, leading to investor losses.
- Loss Recognition Delay: The company utilized a 180-day cliff policy to delay recognizing losses on uncollectable accounts, which resulted in a failure to accurately reflect its financial condition in reports, exacerbating investor losses.
- Insufficient Liability Insurance: Ardent Health failed to maintain adequate levels of professional malpractice liability insurance, which could expose the company to greater financial risks in the event of legal actions, potentially impacting its operational stability going forward.
See More
Ardent Health Faces Class Action Lawsuit
- Lawsuit Background: Bragar Eagel & Squire has filed a class action lawsuit against Ardent Health (ARDT) on behalf of investors who purchased securities between July 18, 2024, and November 12, 2025, alleging failure to timely recognize uncollectible accounts, resulting in investor losses.
- Financial Missteps: Ardent Health reported a $43 million revenue decrease in Q3 2025, primarily due to a transition to a new revenue accounting system and revised assessments of historical collection trends, leading to a 34% drop in stock price in one day.
- Insurance Gaps: The complaint highlights that Ardent Health did not maintain sufficient professional malpractice liability insurance, raising concerns about its ability to cover claims arising from its operations, which further exacerbates investor anxiety.
- Investor Action: Investors must apply by March 9, 2026, to be appointed as lead plaintiffs in the lawsuit, with Bragar Eagel & Squire offering free consultations and encouraging affected investors to reach out to understand their legal rights.
See More
Ardent Health Faces Class Action Lawsuit
- Lawsuit Background: Bronstein, Gewirtz & Grossman LLC has filed a class action lawsuit against Ardent Health and certain officers, alleging violations of federal securities laws from July 18, 2024, to November 12, 2025, seeking damages for affected investors.
- Financial Misstatements: The complaint alleges that Ardent Health overstated its Q3 2025 revenue due to inadequate assessments of accounts receivable collectability following a transition to a new revenue accounting system, misleading investors about the company's financial health.
- EBITDA Guidance Reduction: The company anticipates a $57.5 million reduction in its 2025 EBITDA guidance, approximately 9.6%, primarily due to persistent industry-wide cost pressures and payer denials, which further undermines investor confidence.
- Investor Action Recommendations: Affected investors have until March 9, 2026, to request lead plaintiff status, with the law firm operating on a contingency fee basis, thereby minimizing legal risks for investors seeking recovery.
See More
Ardent Health Securities Class Action Notice
- Class Action Initiation: Rosen Law Firm reminds investors who purchased Ardent Health securities between July 18, 2024, and November 12, 2025, to apply as lead plaintiffs by March 9, 2026, or risk not being represented in the lawsuit.
- Compensation Mechanism: Participants can receive compensation through a contingency fee arrangement without upfront costs, indicating a low-risk legal avenue for affected investors, which may encourage more to join the action.
- False Statements Exposed: The lawsuit alleges that Ardent Health made false representations regarding its accounts receivable, failing to accurately reflect their collectability, leading to investor losses when the truth was revealed, thereby impacting the company's reputation and future financing capabilities.
- Law Firm's Credentials: Rosen Law Firm is renowned for its successful track record in securities class actions, having recovered over $438 million for investors in 2019 alone, demonstrating its expertise and effectiveness in handling such cases.
See More
Ardent Health Faces Class Action for Securities Fraud
- Lawsuit Background: Bleichmar Fonti & Auld LLP has filed a class action against Ardent Health and its executives, alleging securities fraud after a 33% stock drop on November 12, 2025, due to unrecognized uncollectible receivables.
- Financial Misrepresentation: The lawsuit claims Ardent Health falsely stated it relied on 'detailed reviews of historical collections' for receivables, while actually using a 180-day cliff to delay loss recognition, undermining investor confidence.
- Stock Price Impact: Following the announcement of a $43 million revenue decrease and a $54 million increase in professional liability reserves on November 12, 2025, Ardent Health's stock plummeted from $14.05 to $9.30, reflecting a drop of over 33%.
- Legal Consequences: Investors have until March 9, 2026, to apply to lead the case, which could impose legal liabilities on Ardent Health's executives and affect the company's future operations and financial health.
See More
Class Action Lawsuits Filed Against Varonis and Ardent Health
- Varonis Lawsuit Overview: Shareholders of Varonis Systems, Inc. are facing losses from February 4 to October 28, 2025, due to the company's failure to disclose its ability to sustain growth, leading to a misunderstanding of its prospects, with a class action deadline of March 9, 2026.
- Ardent Lawsuit Details: Similarly, shareholders of Ardent Health, Inc. from July 18, 2024, to November 12, 2025, encountered issues as the company misrepresented the collectability of accounts receivable, resulting in a misjudgment of its financial health, with the same class action deadline of March 9, 2026.
- Legal Consultation Advice: The Law Offices of Frank R. Cruz remind investors who suffered losses during the specified periods to contact the firm to understand their legal rights, providing contact details including phone and email.
- Class Action Participation Note: Investors need not take immediate action to be part of the class action, and the law firm offers various contact methods for shareholders to obtain more information and consultation.
See More
Class Action Lawsuit Reminder Against Ardent Health, Inc.
- Class Action Notification: The Schall Law Firm reminds investors of a class action lawsuit against Ardent Health, Inc. (NYSE: ARDT) for securities purchased between July 18, 2024, and November 12, 2025, urging affected investors to contact the firm by March 9, 2026, to participate.
- False Statement Allegations: The complaint alleges that Ardent made false and misleading statements, claiming reliance on 'detailed reviews of historical collections' to assess collectible accounts receivable, which was not the case, leading to investor losses.
- Loss Recognition Delay: The company utilized a 180-day cliff policy to delay recognizing losses on uncollectable accounts, which resulted in a failure to accurately reflect its financial condition in reports, exacerbating investor losses.
- Insufficient Liability Insurance: Ardent Health failed to maintain adequate levels of professional malpractice liability insurance, which could expose the company to greater financial risks in the event of legal actions, potentially impacting its operational stability going forward.
See More
Ardent Health Faces Class Action Lawsuit
- Lawsuit Background: Bragar Eagel & Squire has filed a class action lawsuit against Ardent Health (ARDT) on behalf of investors who purchased securities between July 18, 2024, and November 12, 2025, alleging failure to timely recognize uncollectible accounts, resulting in investor losses.
- Financial Missteps: Ardent Health reported a $43 million revenue decrease in Q3 2025, primarily due to a transition to a new revenue accounting system and revised assessments of historical collection trends, leading to a 34% drop in stock price in one day.
- Insurance Gaps: The complaint highlights that Ardent Health did not maintain sufficient professional malpractice liability insurance, raising concerns about its ability to cover claims arising from its operations, which further exacerbates investor anxiety.
- Investor Action: Investors must apply by March 9, 2026, to be appointed as lead plaintiffs in the lawsuit, with Bragar Eagel & Squire offering free consultations and encouraging affected investors to reach out to understand their legal rights.
See More
Ardent Health Faces Class Action Lawsuit
- Lawsuit Background: Bronstein, Gewirtz & Grossman LLC has filed a class action lawsuit against Ardent Health and certain officers, alleging violations of federal securities laws from July 18, 2024, to November 12, 2025, seeking damages for affected investors.
- Financial Misstatements: The complaint alleges that Ardent Health overstated its Q3 2025 revenue due to inadequate assessments of accounts receivable collectability following a transition to a new revenue accounting system, misleading investors about the company's financial health.
- EBITDA Guidance Reduction: The company anticipates a $57.5 million reduction in its 2025 EBITDA guidance, approximately 9.6%, primarily due to persistent industry-wide cost pressures and payer denials, which further undermines investor confidence.
- Investor Action Recommendations: Affected investors have until March 9, 2026, to request lead plaintiff status, with the law firm operating on a contingency fee basis, thereby minimizing legal risks for investors seeking recovery.
See More
Ardent Health Securities Class Action Notice
- Class Action Initiation: Rosen Law Firm reminds investors who purchased Ardent Health securities between July 18, 2024, and November 12, 2025, to apply as lead plaintiffs by March 9, 2026, or risk not being represented in the lawsuit.
- Compensation Mechanism: Participants can receive compensation through a contingency fee arrangement without upfront costs, indicating a low-risk legal avenue for affected investors, which may encourage more to join the action.
- False Statements Exposed: The lawsuit alleges that Ardent Health made false representations regarding its accounts receivable, failing to accurately reflect their collectability, leading to investor losses when the truth was revealed, thereby impacting the company's reputation and future financing capabilities.
- Law Firm's Credentials: Rosen Law Firm is renowned for its successful track record in securities class actions, having recovered over $438 million for investors in 2019 alone, demonstrating its expertise and effectiveness in handling such cases.
See More
Ardent Health Faces Class Action for Securities Fraud
- Lawsuit Background: Bleichmar Fonti & Auld LLP has filed a class action against Ardent Health and its executives, alleging securities fraud after a 33% stock drop on November 12, 2025, due to unrecognized uncollectible receivables.
- Financial Misrepresentation: The lawsuit claims Ardent Health falsely stated it relied on 'detailed reviews of historical collections' for receivables, while actually using a 180-day cliff to delay loss recognition, undermining investor confidence.
- Stock Price Impact: Following the announcement of a $43 million revenue decrease and a $54 million increase in professional liability reserves on November 12, 2025, Ardent Health's stock plummeted from $14.05 to $9.30, reflecting a drop of over 33%.
- Legal Consequences: Investors have until March 9, 2026, to apply to lead the case, which could impose legal liabilities on Ardent Health's executives and affect the company's future operations and financial health.
See More
